Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as (OMP-18R5)
Vantictumab · 2 trials · 3 indications
The maximum tolerated dose (MTD) will be determined in patients treated with vantictumab in combination with weekly nab-paclitaxel
| Arm | Type | Description |
|---|---|---|
| Docetaxel | EXPERIMENTAL | Drug: Docetaxel - administered intravenously |
| vantictumab | EXPERIMENTAL | Drug: vantictumab - administered intravenously |
| Vanctictumab (OMP-18R5) | EXPERIMENTAL | Vantictumab will be administered by intravenous (IV) infusion. |
| Nab-Paclitaxel | EXPERIMENTAL | Nab-Paclitaxel will be administered by intravenous (IV) infusion. |
| Gemcitabine | EXPERIMENTAL | Gemcitabine will be administered by intravenous (IV) infusion. |
| Name | Type | Description |
|---|---|---|
| Docetaxel | DRUG | Docetaxel will be administered IV. |
| vantictumab | DRUG | Vantictumab will be administered intravenously |
| Nab-Paclitaxel | DRUG | Nab-Paclitaxel will be administered by intravenous (IV) infusion. |
| Gemcitabine | DRUG | Gemcitabine will be administered by intravenous (IV) infusion. |
Inclusion Criteria: * Signed Informed Consent Form * Age ≥18 years * Histologically documented recurrent or advanced (Stage IV) NSCLC * Eastern CooperativeOncology Group (ECOG) performance status of 0 or 1 * All acute treatmentrelated toxicity from prior therapy must have resolved to Grade ≤ 1 prio...
Top 20 of 69 competitors
Vantictumab is an investigational monoclonal antibody being developed by Mereo BioPharma Group plc for the treatment of pancreatic cancer and solid tumors. It is in Phase 1 clinical development and is not approved for any indication. It was studied in combination with chemotherapy agents in patients with advanced disease.
Vantictumab targets the Frizzled receptors FZD1, FZD2, FZD5, FZD7, and FZD8. It acts as an antagonist of these receptors, which are part of the Wnt signaling pathway. By binding these targets, vantictumab is designed to interfere with Wnt pathway signaling in cancer cells.
Vantictumab is being developed by Mereo BioPharma Group plc, which trades on the Nasdaq under the ticker MREO. The company holds the development program for this monoclonal antibody, which is being investigated in oncology indications including pancreatic cancer and solid tumors.
Vantictumab is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The completed Phase 1 studies evaluated the drug in combination with chemotherapy in patients with pancreatic cancer and solid tumors.
Vantictumab has been evaluated in two completed Phase 1 trials. NCT02005315 studied vantictumab with nab-paclitaxel and gemcitabine in previously untreated stage IV pancreatic cancer, enrolling 30 patients. NCT01957007 studied vantictumab with docetaxel in previously treated NSCLC, enrolling 34 patients. Both trials were conducted in the United States.
Yes, Vantictumab is also known as OMP-18R5. The two names refer to the same monoclonal antibody. OMP-18R5 was the earlier designation used in the clinical trial titles, including NCT02005315 and NCT01957007, while vantictumab is the current name for the same investigational agent.